Status:
COMPLETED
Omega-3 Fatty Acids for Autism Treatment
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Autism Speaks
Conditions:
Autism
Eligibility:
All Genders
3-8 years
Phase:
PHASE2
Brief Summary
Omega-3 fatty acids are among the most commonly used CAM (Complementary Alternative Medical) therapies, and have been reported to be currently used by 28.7% of children with autism. Two published case...
Detailed Description
Clinical measures will be used to assess diagnosis and efficacy. All clinical assessments will take place at the M.I.N.D. Institute. Baseline and termination measures will include the Aberrant Behavio...
Eligibility Criteria
Inclusion
- Diagnosis of autism as defined by DSM-IV TR and scores above the cutoff on the Autism Diagnostic Observation Scale (ADOS) and the Social Communication Questionnaire (SCQ)
- Age three to eight years
- Non-verbal IQ of 50 or above
- Children on a stable medical regimen for the past 2 months and no plans to change medical therapy for the study period
Exclusion
- Individuals with allergy or hypersensitivity to fish or nuts
- Diabetes
- Bleeding disorder, current use of anticoagulant or anti-platelet therapy, or recent surgery
- Clinical evidence of seizure disorder
- Cancer
- Fragile X or other known genetic cause of autism
- Perinatal brain injury
- Evidence for malnutrition seen in abnormal albumin level
- Other serious medical illness
- Current use of omega-3 fatty acids
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00786799
Start Date
August 1 2008
End Date
September 1 2009
Last Update
August 31 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UC San Francisco
San Francisco, California, United States, 94143